Provider review
Found Tirzepatide Review
Released: · Last reviewed:
Found is reviewed here against a fixed evidence checklist: advertised and all-in tirzepatide pricing, mandatory fees, dose coverage, pharmacy, clinician model and cancellation terms. Found's compounded tirzepatide prices, read on its own page on October 15, 2026: $219 first month, then $359 per 4 weeks · $309 (3-month) · $289 (6-month) · $239 (12-month), per 4-week cycle. Its cheapest standing plan costs $3,107 for twelve months (13 cycles × $239), 13 of 15 in our index by twelve-month cost. Cash-pay track; billed per 4-week cycle (13 a year).
Key takeaways
- Cheapest standing plan: $3,107 for twelve months (13 cycles × $239); $359 per 4 weeks month to month.
- Mandatory fees: Cash-pay plan; no separate membership fee printed on the plan page (read October 15, 2026).
- Compounding pharmacy, licence, facility type, clinicians, states, and cancellation terms are all unverified and shown as Verification Pending rather than inferred.
- Compounded tirzepatide is not FDA approved and is not reviewed by the FDA before sale.
| Provider | Found |
|---|---|
| Operating status | Active |
| Program type | Primary national / major telehealth |
| Tirzepatide price (as captured) | $219 first month, then $359 per 4 weeks · $309 (3-month) · $289 (6-month) · $239 (12-month), per 4-week cycle (read 2026-10-15) |
| Normalised monthly cost | $239 per 4 weeks on the 12-month cash plan |
| Mandatory fees | Cash-pay plan; no separate membership fee printed on the plan page (read October 15, 2026) |
| Medication included | Yes: the price includes medication |
| Billing cadence | Plan-specific |
| Compounding pharmacy | Verification Pending |
| Pharmacy licence | Verification Pending |
| Facility type (503A/503B) | Verification Pending |
| Named clinicians | Verification Pending |
| States served | Verification Pending |
| Dose coverage | Verification Pending |
| Shipping terms | Verification Pending |
| Cancellation policy | Verification Pending |
| Refund policy | Verification Pending |
| Auto-renewal terms | Verification Pending |
| Evidence source | Official provider |
| Source confidence | Moderate |
| Price verified | 2026-10-15 |
What is the verdict on this provider?
Found publishes a standing price with medication and every required fee inside it, so it can be compared like-for-like. Its cheapest standing plan costs $3,107 a year, 13 of 15 in our index. Price is one input: pharmacy, clinician and cancellation fields below remain unverified unless stated.
What does tirzepatide actually cost at Found?
Found's compounded tirzepatide prices, read on its own page on October 15, 2026: $219 first month, then $359 per 4 weeks · $309 (3-month) · $289 (6-month) · $239 (12-month), per 4-week cycle. Its cheapest standing plan costs $3,107 for twelve months (13 cycles × $239), 13 of 15 in our index by twelve-month cost. Cash-pay track; billed per 4-week cycle (13 a year).
Source: joinfound.com. Confirm the recurring price after any first month, every mandatory fee and the price at your maintenance dose at checkout before enrolling.
What does the captured source actually state?
| Field | Text as captured from the provider's own page |
|---|---|
| Tirzepatide pricing, as published | Compounded GLP-1 program advertised from $99/month; exact medication-specific quote varies |
| Semaglutide pricing, as published | Compounded GLP-1 program advertised from $99/month |
| Fee structure, as published | Program pricing varies; verify whether medication and membership are bundled |
| Medication inclusion, as published | Varies |
| Billing cadence, as published | Plan-specific |
| Evidence type | Current advertised starting price |
| Capture caveat | “From” pricing is not an all-dose or all-formulation guarantee. |
How should the Found pricing structure be read?
The same source also publishes semaglutide pricing, which is useful context: a provider pricing both drugs allows a switch without changing provider, though the two are not interchangeable and any change is a prescriber decision.
Source confidence for this record is recorded as Moderate, which is why the figures above are presented as captured text rather than asserted as the current price.
What has not been verified?
What should you confirm before enrolling?
- The recurring price after any introductory or first-month rate, in writing.
- Every mandatory fee: membership, consultation, shipping, and any dose-related surcharge.
- Which compounding pharmacy dispenses, its state licence number, and whether it is 503A or 503B.
- What happens to the price when your dose increases.
- The cancellation method, notice period, and whether prepaid months are refundable.
- Whether the plan auto-renews and how to stop it.
- That a licensed clinician reviews your intake and is reachable for side-effect questions.
What are the alternatives?
Primary source: Found pricing page · captured 2026-07-20. “From” pricing is not an all-dose or all-formulation guarantee.
| Group | Verified | Required for full review |
|---|---|---|
| Pricing fields held | 2 | 5 |
| Pharmacy fields held | 0 | 4 |
| Policy fields held | 0 | 4 |
Why is this provider not ranked on cost?
| Test | Result for this provider |
|---|---|
| Recurring price stated | Yes |
| Medication included | Varies |
| All mandatory fees confirmed | No |
| Classification | from teaser |
| Published reason | Advertised as a “from” starting price, not a recurring all-in cost |
What is Found's status after the compounding change?
Found was captured on 2026-07-20 advertising compounded tirzepatide. That capture predates nothing — it is recent — but the legal basis for the product it describes changed before it was taken. Compounding of tirzepatide was permitted only while the drug sat on the FDA shortage list. The shortage was declared resolved on 2 October 2024 and reaffirmed by declaratory order on 19 December 2024, and enforcement discretion ended on 18 February 2025 for 503A pharmacies and 19 March 2025 for 503B outsourcing facilities.
This site records Found's prices with the date each was read and compares them only on a like-for-like basis (see the position table). If Found continues to advertise compounded tirzepatide, the useful question is not whether the price is competitive but what legal basis the product is supplied under and which state-licensed pharmacy dispenses it. Neither is verified in this record.
| Question | Position for Found | How this site treats it |
|---|---|---|
| Was compounded tirzepatide advertised at capture? | Yes | Recorded with its read date |
| Operating status at capture | Active | Reported as captured; not re-verified since |
| Legal basis for continued compounded supply | Not disclosed in the captured source | Verification Pending — not inferred |
| Dispensing pharmacy identity | Not disclosed | Verification Pending |
| Whether approved products are now offered | Not established in this record | Verification Pending — ask the provider directly |
How was Found's pricing classified?
Every provider on this site passes through the same four-part price test before it can appear in a cost ranking. The test asks whether the captured source states a recurring price, whether medication is included in that price, whether every mandatory fee is identified, and whether the figure describes the standard subcutaneous injection rather than an alternative formulation. Found is assessed below against each part in turn.
| Test | Result for this provider | Why it matters |
|---|---|---|
| A recurring price is stated | Yes | Compounded GLP-1 program advertised from $99/month; exact medication-specific quote varies |
| Medication is included in that price | Varies | Determines whether the figure is the whole cost or only part of it |
| Every mandatory fee is identified | Program pricing varies; verify whether medication and membership are bundled | A separate recurring membership or care fee changes the real monthly outlay |
| The figure describes the standard injection | not applicable | Microdose, ODT, sublingual and troche preparations are not comparable with an injection |
| Classification result | from teaser | Advertised as a “from” starting price, not a recurring all-in cost |
Found does not pass, and the reason is specific: Advertised as a “from” starting price, not a recurring all-in cost. This is a statement about disclosure, not about service quality or value. A provider may be excellent and still publish pricing in a form that cannot be normalised — and equally, a provider that publishes a complete price may not be the right choice on any other dimension. The exclusion means only that a like-for-like cost comparison is not currently possible.
How does Found compare with the other programs in our index?
Found's cheapest standing plan costs $3,107 for twelve months (13 cycles × $239), which places it 13 of 15 by twelve-month cost in our index as of November 8, 2026. The range runs from $1,368 (Mondae, two prepaid 6-month plans) to $3,640 (Enhance.MD); the median is $2,568. Month to month, Found charges $359 per 4 weeks.
| # | Program | Lowest monthly | Plan behind it | Month to month | 12-month cost | How the 12 months are bought | Source · read |
|---|---|---|---|---|---|---|---|
| 1 | Mondae | $114 | $114/mo on a prepaid 6-month plan ($684) | $126 | $1,368 | two 6-month plans at $684 | mondae.com · 2026-10-15 |
| 2 | NexLife | $115 | $115/mo on a 12-month plan ($1,380) | $129 | $1,380 | 12-month plan | nexlife.us · 2026-11-06 |
| 3 | TRYM Health | $125 | $125/mo on the 12-month plan ($1,500 one-time payment) | $180 | $1,500 | 12-month one-time payment | trymhealth.com · 2026-11-08 |
| 4 | Eden | $129 | $129 every month | $129 | $1,548 | 12 × $129 | eden.health · 2026-10-15 |
| 5 | Sprout Health | $149 | $149/mo on the 12-month plan ($1,788 up front) | $199/4 wk | $1,788 | 12-month plan billed up front | joinsprouthealth.com · 2026-10-15 |
| 6 | He & She MD | $159 | $159/mo on the 12-month plan | $339 | $1,908 | 12 × $159 | heandshemd.com · 2026-10-15 |
| 7 | Bodybuilding Health+ | $174.67 | $174.67/mo on 6 months | $209 | $2,096 | two 6-month plans | bbhealthplus.com · 2026-10-15 |
| 8 | TelePep | $214 | $214/mo on the annual plan ($2,568 up front) | $249 | $2,568 | annual plan up front | telepeptide.org · 2026-10-15 |
| 9 | Yucca Health | $225 | $225/mo on 6 months ($1,350) | $258 | $2,700 | two 6-month plans | tryyucca.com · 2026-09-04 (carried) |
| 10 | Join Josie | $233.25 | $233.25/mo on 12 months ($2,799) | $349 | $2,799 | 12-month plan | joinjosie.com · 2026-10-15 |
| 11 | Pallas Health | $239 | $239/mo average on the annual plan | $299/4 wk | $2,868 | 12 × $239 average | pallashealth.co · 2026-10-15 |
| 12 | Fridays | $240 | $240/mo on the annual plan (paid annually) | $359 | $2,880 | 12 × $240 | joinfridays.com · 2026-10-15 |
| 13 | Found | $239 | $239 per 4 weeks on the 12-month cash plan | $359/4 wk | $3,107 | 13 cycles × $239 | joinfound.com · 2026-10-15 |
| 14 | Zappy Health | $299 | $299/mo on 6 months ($1,794) | $349 | $3,588 | two 6-month plans | zappyhealth.com · 2026-11-08 |
| 15 | Enhance.MD | $280 | $280 per 4 weeks on the 12-month plan | $329/4 wk | $3,640 | 13 cycles × $280 | enhance.md · 2026-10-15 |
What else does Found's captured record contain?
The full record held for Found is reproduced below. This site publishes the underlying capture rather than only its own summary, so a reader can see exactly what the interpretation rests on and disagree with it if the reading looks wrong.
| Field | Value held for this provider |
|---|---|
| Programme category | Primary national / major telehealth |
| Operating status | Active |
| Tirzepatide pricing, as captured | Compounded GLP-1 program advertised from $99/month; exact medication-specific quote varies |
| Semaglutide pricing, as captured | Compounded GLP-1 program advertised from $99/month |
| Mandatory fees, as captured | Program pricing varies; verify whether medication and membership are bundled |
| Medication inclusion | Varies |
| Billing cadence | Plan-specific |
| Evidence type | Current advertised starting price |
| Capture caveats | “From” pricing is not an all-dose or all-formulation guarantee. |
| Source | Official provider |
| Source confidence | Moderate |
| Price verified | 2026-07-20 |
Found's semaglutide pricing is recorded because the relationship between a provider's semaglutide and tirzepatide pricing is informative on its own. Semaglutide is typically the cheaper of the two in this market, and a provider whose tirzepatide premium is unusually large or unusually small relative to its semaglutide rate is worth asking about — it can reflect different pharmacy sourcing, different dose coverage, or a promotional structure that will not persist. For Found the captured semaglutide text reads: Compounded GLP-1 program advertised from $99/month
The capture for Found is rated moderate confidence. That rating reflects genuine ambiguity in the source — typically a page that presents a starting figure without stating which dose, formulation, or commitment length it applies to, or that presents different figures on different landing pages. Moderate confidence is why the figure is reported but not ranked.
What should you ask Found before enrolling?
These questions are selected against the specific gaps in Found's record rather than being a generic checklist. Ask them in writing and keep the reply: a verbal assurance from a sales channel is not a contractual term, and terms are what govern a dispute.
- What is the recurring monthly price after any introductory or first-month rate?
- Is the medication itself included in that price, or billed separately?
- What recurring fees apply on top of the medication, and are any of them waived initially?
- Which dose, formulation, and commitment length does the advertised starting price actually apply to?
- What does the same programme cost at a standard maintenance dose rather than the starting tier?
- Which compounding pharmacy prepares the medication, and what is its state licence number?
- Is that pharmacy a 503A compounder or a 503B outsourcing facility?
- Does the price change when the dose increases to 10 mg or 15 mg?
- What concentration is dispensed, in mg/mL, and what beyond-use date is assigned?
- How is the plan cancelled, what notice is required, and are prepaid months refundable?
- Does the plan auto-renew, and how is renewal stopped?
- Which licensed clinician reviews the intake, and how are side-effect questions handled?
A provider that answers all of these in writing has demonstrated something meaningful about how it operates. A provider that will not name its compounding pharmacy before payment has also told you something, and it is worth weighing that refusal as evidence in its own right.
Why is this review shorter than the others?
Because the evidence held for Found does not support more. Its captured pricing (Advertised as a “from” starting price, not a recurring all-in cost) cannot be reduced to a comparable recurring figure, and its pharmacy, clinician, states, dose-coverage and cancellation fields are all unverified. Writing further would mean inferring facts rather than reporting them.
This site treats a short page as the correct output in that situation. The alternative — padding a review with general commentary that would read identically for any provider — would give an impression of thoroughness the underlying evidence does not justify, and would make it harder for a reader to see which providers have actually disclosed something. The length of this page is itself a finding.
Current approved-product pathways: Zepbound self-pay from $299 per month at the starting dose. Full pathway comparison.
What do the technical terms on this page mean?
Definitions for the 10 technical terms this page uses, including 503A, 503B, GLP-1, auto-renewal — in the specific sense used above.
| 503A | A pharmacy that compounds patient-specific preparations against individual prescriptions. It is licensed by a state board of pharmacy and is not subject to the same federal manufacturing requirements as a 503B facility. |
|---|---|
| 503B | An outsourcing facility that may compound in larger batches without individual prescriptions. It registers with the FDA and is subject to current good manufacturing practice requirements, though registration is still not product approval. |
| GLP-1 | Glucagon-like peptide-1. An incretin hormone that slows gastric emptying, signals satiety to the brain, stimulates glucose-dependent insulin release, and suppresses inappropriate glucagon secretion. |
| auto-renewal | A term under which a plan renews automatically unless cancelled. Combined with a notice period, it determines how much money is at risk if treatment stops. |
| beyond-use date | The date after which a compounded preparation should not be used. It is assigned by the compounding pharmacy based on its own conditions, and is typically much shorter than a manufacturer expiry date derived from formal stability testing. |
| compounded | Prepared by a pharmacy rather than manufactured under an approved application. Compounded tirzepatide is not FDA approved and has not been evaluated in any randomised trial. |
| effective monthly cost | The recurring amount actually paid each month once every mandatory fee is included. It is frequently higher than the advertised medication price, which is why this site normalises before ranking. |
| membership fee | A recurring charge separate from the medication price, common in telehealth weight programmes. It can add $40 to $80 per month and frequently reverses which provider is genuinely cheaper. |
| mg/mL | Milligrams of drug per millilitre of liquid — the concentration. Two vials containing the same nominal dose can require different injection volumes if their concentrations differ, which is why this site does not publish volume calculations. |
| subcutaneous | Beneath the skin. Tirzepatide is given by subcutaneous injection, usually into the abdomen, thigh, or upper arm. |
Frequently asked questions
How much does tirzepatide cost at Found?
Found's compounded tirzepatide prices, read on its own page on October 15, 2026: $219 first month, then $359 per 4 weeks · $309 (3-month) · $289 (6-month) · $239 (12-month), per 4-week cycle. Its cheapest standing plan costs $3,107 for twelve months (13 cycles × $239), 13 of 15 in our index by twelve-month cost. Cash-pay track; billed per 4-week cycle (13 a year). Confirm the recurring price and every mandatory fee at checkout before enrolling.
Which pharmacy does Found use?
Not verified. The compounding pharmacy identity, its state licence, and whether it is a 503A or 503B facility have not been confirmed first-party, so nothing is asserted.
Is Found cheaper than other providers?
On twelve-month cost Found ranks 13 of 15 in our index ($3,107 on its cheapest standing plan). The two lowest are Mondae ($1,368) and NexLife ($1,380), and the median is $2,568. Read October 15, 2026.
Is compounded tirzepatide FDA approved?
No. Compounded tirzepatide is not FDA approved and is not reviewed by the FDA for safety, effectiveness, or quality before sale.
Sources for this page
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
| 2026-09-04 | Ranked set and category median rebuilt from the 2026-09-04 dataset (7 of 29 records ranked; NexLife re-read live, Yucca Health and a program since removed from this site added). Relationship disclosure updated: NexLife is a disclosed commercial partner of the publisher; this provider's own record is unchanged. |
| 2026-11-08 | Price record updated to the October 15, 2026 read; checklist, verdict, cost section, position table and FAQ answers rebuilt; dated notice added above the older capture. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.